Slate Medicines
Last verified 2026-06-17. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $130.0Mattributed |
|---|---|
| Latest round | series-a, $130.0M, 2026-02-24attributed |
| Founded | 2025 |
| Headquarters | Raleigh |
| Industry | healthcare |
| Stage | series-a |
| Website | slatemedicines.com |
Slate Medicines develops treatments for migraine and other headache disorders, led by SLTE-1009, a subcutaneous anti-PACAP monoclonal antibody. It targets migraine patients underserved by existing therapies such as CGRP inhibitors. By blocking PACAP rather than CGRP, the drug pursues a distinct pathway for harder-to-treat patients.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-02-24 | series-a | $130.0M | undisclosed |
Detected tech stack
cdnjs, cloudflare, cloudflare bot management, doubleclick floodlight, google analytics, google tag manager, hsts, http/3, jquery 3.7.1, jquery migrate 3.4.1, kinsta, mysql
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $130.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $130.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | slatemedicines.com, read 2026-06-17 |
| Description | self-reported | slatemedicines.com, read 2026-06-17 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.